{
    "clinical_study": {
        "@rank": "40331", 
        "arm_group": [
            {
                "arm_group_label": "DX-2930, Cohort 1", 
                "arm_group_type": "Experimental", 
                "description": "DX-2930 administered twice, two weeks apart"
            }, 
            {
                "arm_group_label": "DX-2930, Cohort 2", 
                "arm_group_type": "Experimental", 
                "description": "DX-2930 administered twice, two weeks apart"
            }, 
            {
                "arm_group_label": "DX-2930, Cohort 3", 
                "arm_group_type": "Experimental", 
                "description": "DX-2930 administered twice, two weeks apart"
            }, 
            {
                "arm_group_label": "Placebo", 
                "arm_group_type": "Placebo Comparator", 
                "description": "Placebo"
            }
        ], 
        "brief_summary": {
            "textblock": "The purpose of this study is to evaluate the safety, tolerability, and PK profile of\n      multiple subcutaneous administrations of DX-2930 across a range of doses in HAE subjects."
        }, 
        "brief_title": "Double-Blind, Multiple Ascending Dose Study to Assess Safety, Tolerability and Pharmacokinetics of DX-2930 in Hereditary Angioedema Subjects", 
        "completion_date": {
            "#text": "March 2015", 
            "@type": "Anticipated"
        }, 
        "condition": "Hereditary Angioedema", 
        "condition_browse": {
            "mesh_term": [
                "Angioedema", 
                "Angioedemas, Hereditary"
            ]
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  At least 18 years of age at the time of screening.\n\n          -  Documented diagnosis of HAE (Type I or II)\n\n          -  Experiencing \u22652 HAE attacks per year, with at least 1 attack in the past 6 months\n             reported by the subject.\n\n          -  Willing and able to read, understand, and sign an informed consent form.\n\n          -  Females of childbearing potential must agree to be abstinent or else use acceptable\n             forms of contraception throughout study\n\n          -  Males with female partners of childbearing potential must agree to be abstinent or\n             use a medically acceptable form of contraception throughout study.\n\n        Exclusion Criteria:\n\n          -  Exposure to an investigational drug or device within 90 days prior to study.\n\n          -  History of exposure within the past 5 years to a monoclonal antibody or recombinant\n             protein bearing an Fc domain.\n\n          -  Concomitant diagnosis of another form of chronic angioedema\n\n          -  Use of long-term prophylaxis for HAE within 90 days prior to study.\n\n          -  Use of C1-INH that exceeds a total of 30 days within the past 90 days prior to study;\n             any use of C1-INH within 7 days prior to study.\n\n          -  Exposure to angiotensin-converting enzyme (ACE) inhibitors or any estrogen-containing\n             medications with systemic absorption within 90 days prior to study.\n\n          -  Exposure to androgens within 90 days prior to study.\n\n          -  Presence of an indwelling catheter.\n\n          -  Diagnosis of HIV.\n\n          -  Active liver disease or liver function test abnormalities\n\n          -  History of substance abuse or dependence.\n\n          -  Pregnancy or breastfeeding.\n\n          -  Any condition that, in the opinion of the Investigator, may compromise their safety\n             or compliance, preclude successful conduct of the study, or interfere with\n             interpretation of the results"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "18", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "March 17, 2014", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT02093923", 
            "org_study_id": "DX-2930-02"
        }, 
        "intervention": [
            {
                "arm_group_label": [
                    "DX-2930, Cohort 1", 
                    "DX-2930, Cohort 2", 
                    "DX-2930, Cohort 3"
                ], 
                "description": "DX-2930 is a recombinant, Chinese hamster ovary (CHO) cell expressed, fully human immunoglobulin IgG1, kappa light chain, monoclonal antibody", 
                "intervention_name": "DX-2930", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": [
                    "DX-2930, Cohort 1", 
                    "DX-2930, Cohort 2", 
                    "DX-2930, Cohort 3", 
                    "Placebo"
                ], 
                "description": "Placebo", 
                "intervention_name": "Placebo", 
                "intervention_type": "Drug"
            }
        ], 
        "is_fda_regulated": "Yes", 
        "is_section_801": "No", 
        "keyword": "HAE", 
        "lastchanged_date": "May 28, 2014", 
        "location": [
            {
                "facility": {
                    "address": {
                        "city": "Walnut Creek", 
                        "country": "United States", 
                        "state": "California", 
                        "zip": "94598"
                    }, 
                    "name": "Joshua S. Jacobs, MD"
                }, 
                "investigator": {
                    "last_name": "Joshua S Jacobs, MD", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Boston", 
                        "country": "United States", 
                        "state": "Massachusetts", 
                        "zip": "02114"
                    }, 
                    "name": "Aleena Banerji, MD"
                }, 
                "investigator": {
                    "last_name": "Aleena Banerji, MD", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Cincinnati", 
                        "country": "United States", 
                        "state": "Ohio", 
                        "zip": "45267"
                    }, 
                    "name": "Jonathan A. Bernstein, MD"
                }, 
                "investigator": {
                    "last_name": "Jonathan A Bernstein, MD", 
                    "role": "Principal Investigator"
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Lake Oswego", 
                        "country": "United States", 
                        "state": "Oregon", 
                        "zip": "97035"
                    }, 
                    "name": "James W. Baker, MD"
                }, 
                "investigator": {
                    "last_name": "James W Baker, MD", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Dallas", 
                        "country": "United States", 
                        "state": "Texas", 
                        "zip": "75231"
                    }, 
                    "name": "William R. Lumry, MD"
                }, 
                "investigator": {
                    "last_name": "William R Lumry, MD", 
                    "role": "Principal Investigator"
                }, 
                "status": "Not yet recruiting"
            }
        ], 
        "location_countries": {
            "country": "United States"
        }, 
        "number_of_arms": "4", 
        "official_title": "A Phase 1b, Double-Blind, Multiple Ascending Dose Study to Assess Safety, Tolerability and Pharmacokinetics of DX-2930 in Hereditary Angioedema Subjects", 
        "overall_contact": {
            "email": "riarrobino@dyax.com", 
            "last_name": "Ryan Iarrobino", 
            "phone": "617-250-5574"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "United States: Food and Drug Administration", 
            "has_dmc": "No"
        }, 
        "phase": "Phase 1", 
        "primary_completion_date": {
            "#text": "March 2015", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "measure": "proportion of patients with non-serious and serious adverse events", 
            "safety_issue": "Yes", 
            "time_frame": "through 4 months"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT02093923"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": {
            "measure": "DX-2930 plasma level", 
            "safety_issue": "No", 
            "time_frame": "through 4 months"
        }, 
        "source": "Dyax Corp.", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Dyax Corp.", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "April 2014", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "May 2014"
    }
}